Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
Mario Boccadoro, Filippo Marmont, M Tribalto, Giuseppe Avvisati, A Andriani, Tiziano Barbui, Maria Cantonetti, M Carotenuto, Benedetto Comotti, Franco Dammacco
Journal of Clinical Oncology, 1991
Abstract
This research paper explore the methodology and findings associated with Journal of Clinical Oncology. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).
- The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute Leukemia 1979
- Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone. 1982
- Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol). 1982
- Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma. 1982
- Combination chemotherapy for non‐Hodgkin lymphomas: A ten year follow‐up study 1979